{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:19:53Z","timestamp":1773037193484,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to utilize the FDA Adverse Event Reporting System (FAERS) database to systematically investigate the relationship between compound inhaled long-acting bronchodilators for inhalation (ILABs) and cardiovascular adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pharmacovigilance analysis using cardiac adverse event (CAE) reports submitted to FAERS between January 2014 and September 30, 2024. We compared the cardiac toxicity signal intensity of various compound ILABs using the proportional imbalance measurement method. Additionally, we performed subgroup analyses considering factors such as composition, onset time, mortality outcome case information, and concomitant adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our study comprised 3,120 reports on the use of compound ILABs, involving 653 CAEs (454 reports). The most prevalent CAEs observed were atrial fibrillation (14.93%), myocardial infarction (14.37%), cardiac failure congestive (10.96%), cardiac disorder (8.70%), and cardiogenic shock (8.13%). Approximately 20% of CAEs occurred on day 0, and roughly 50% occurred within 90 days. The proportion of CAE reports was similar for triple inhalation formulations and double bronchodilators. But the number of adverse events such as congestive cardiac failure, coronary artery disease, and ventricular extrasystoles associated with triple inhaled formulations was significantly higher than that with dual bronchodilators, with no such reports for the latter. 84.58% of CAE cases were linked to other adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compound ILABs had significant CAE risk signals, especially those of atrial fibrillation, myocardial infarction and heart failure, and the risk signal was stronger in the early stage of drug treatment. Except for a few individual adverse events, the overall CAE risk signal associated with triple inhaled agents (mainly Fluticasone\/umeclidinium\/vilanterol) was comparable to that of dual bronchodilators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1715192","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:29:19Z","timestamp":1773034159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990\u20132019: an update from the global burden of disease study 2019","volume":"59","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12889-025-21680-0","article-title":"The global burden of chronic respiratory diseases attributable to tobacco from 1990 to 2021: a global burden of disease study 2021","volume":"25","author":"Feng","year":"2025","journal-title":"BMC Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2165\/00003495-200565120-00001","article-title":"Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease","volume":"65","author":"Cazzola","year":"2005","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1378\/chest.10-2499","article-title":"Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study","volume":"142","author":"Wilchesky","year":"2012","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1378\/chest.11-1597","article-title":"Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort","volume":"142","author":"Wilchesky","year":"2012","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci Data"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1742-7843.2006.pto_232.x","article-title":"Data mining in spontaneous reports","volume":"98","author":"Bate","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/FJC.0000000000000705","article-title":"Correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable copd: a Bayesian network meta-analysis of randomized controlled trials","volume":"74","author":"Wu","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/pr.119.018150","article-title":"Pharmacology and therapeutics of bronchodilators revisited","volume":"72","author":"Matera","year":"2020","journal-title":"Pharmacol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jfda.2018.12.006","article-title":"Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease","volume":"27","author":"Wang","year":"2019","journal-title":"J Food Drug Anal"},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00408-024-00677-3","article-title":"Cardiovascular events with the use of long-acting muscarinic receptor antagonists: an analysis of the FAERS database 2020\u20132023","volume":"202","author":"Matera","year":"2024","journal-title":"Lung"},{"key":"B21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijcard.2015.04.129","article-title":"Inhaled bronchodilators and the risk of tachyarrhythmias","volume":"190","author":"Lee","year":"2015","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/phar.1684","article-title":"Comparative cardiovascular and cerebrovascular safety of inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a population-based cohort study","volume":"36","author":"Dong","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2147\/COPD.S363997","article-title":"Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists","volume":"17","author":"Rebordosa","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/joim.13348","article-title":"Dual versus single long-acting bronchodilator use could raise acute coronary syndrome risk by over 50%: a population-based nested case-control study","volume":"290","author":"Parkin","year":"2021","journal-title":"J Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e000840","DOI":"10.1136\/bmjresp-2020-000840","article-title":"Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?","volume":"8","author":"Parkin","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1602245","DOI":"10.1183\/13993003.02245-2016","article-title":"Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events","volume":"49","author":"Suissa","year":"2017","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"160123","DOI":"10.1183\/16000617.0123-2016","article-title":"Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities","volume":"26","author":"Corrao","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12890-019-0999-z","article-title":"Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Pulm Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000487182","article-title":"Combination therapy of inhaled indacaterol\/glycopyrronium for chronic obstructive pulmonary disease in the very elderly: is it safe? An electrocardiographic evaluation","volume":"95","author":"Spannella","year":"2018","journal-title":"Respiration"},{"key":"B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/COPD.S433583","article-title":"Cardiovascular events according to inhaler therapy and comorbidities in chronic obstructive pulmonary disease","volume":"19","author":"Kim","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.chest.2021.05.025","article-title":"Comparative effectiveness and safety of different types of inhaled long-acting beta(2)-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting beta(2)-agonist plus inhaled corticosteroid fixed-dose combinations in COPD a propensity score-inverse probability of treatment weighting cohort study","volume":"160","author":"Wang","year":"2021","journal-title":"Chest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1164\/rccm.202312-2311OC","article-title":"Effect of triple therapy on cardiovascular and severe cardiopulmonary events in chronic obstructive pulmonary disease: a post hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS)","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1183\/09059180.00008612","article-title":"Comorbidities of COPD","volume":"22","author":"Cavaill\u00e8s","year":"2013","journal-title":"Eur Respir Rev"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1715192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:29:20Z","timestamp":1773034160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1715192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1715192"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1715192","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1715192"}}